FULCRUM THERAPEUTICS, INC.
Income Statement
| Line Item | Sep 2025 | Jun 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $80.0M | $0 | $871.0K | $759.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $14.3M | $13.0M | $11.7M | $14.6M | $17.3M | $19.8M | $19.0M | $18.2M |
| SG&A Expense | $7.6M | $6.8M | $7.7M | $8.4M | $10.2M | $10.1M | $9.9M | $10.0M |
| Operating Income | $-21.9M | $-19.8M | $-19.4M | $-25.1M | $52.5M | $-29.8M | $-28.0M | $-27.4M |
| Operating Margin | — | — | — | — | 65.6% | — | -3,213.8% | -3,615.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-19.6M | $-17.3M | $-16.6M | $-21.7M | $55.4M | $-26.9M | $-24.8M | $-24.0M |
| Net Margin | — | — | — | — | 69.3% | — | -2,842.3% | -3,164.3% |
| EPS (Basic) | $-0.31 | $-0.28 | $-0.27 | $-0.35 | $0.89 | $-0.43 | $-0.41 | $-0.39 |
| EPS (Diluted) | $-0.31 | $-0.28 | $-0.25 | $-0.35 | $0.87 | $-0.43 | $-0.41 | $-0.39 |
| Shares Outstanding (Basic) | 62.6M | 62.5M | 62.0K | 62.4M | 62.2M | 62.0M | 61.3K | 61.8M |
| Shares Outstanding (Diluted) | 62.6M | 62.5M | 62.0K | 62.4M | 63.6M | 62.0M | 61.3K | 61.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |